Author of

• 36172

  +

  P48 - Small Cell Lung Cancer/NET - Chemo - IO (ID 236)

  • Event: WCLC 2020
  • Type: Posters
  • Track: Small Cell Lung Cancer/NET
  • Presentations: 1
  • Moderators:
  • Coordinates: 1/28/2021, 00:00 - 00:00, ePoster Hall

  • 36186

    +

    P48.11 - Anlotinib Versus Chemotherapy as a Third-Line or Further Treatment for Advanced Small Cell Lung Cancer (ID 675)

    00:00 - 00:00  |  Presenting Author(s): Yue Wang
    • Abstract
    • Slides

    Introduction
    

    The optimal third-line or further treatment for advanced small cell lung cancer (SCLC) remains unclear.Anlotinib,which is a novel multitarget tyrosine kinase inhibitor,could inhibit tumor angiogenesis and proliferative signaling.Therefore,this retrospective study aimed to compare the efficacy and safety of anlotinib versus chemotherapy of patients with advanced SCLC progressing after second-line or further treatment.

    Methods
    

    This study included 55 advanced SCLC patients (n=28 for anlotinib group and n=27 for chemotherapy group) from Shanghai Chest hospital between January 2017 and September 2019.Detailed demographic,survival data,and safety data were collected.Kaplan-Meier method and log-rank test were used to assess median progression-free survival (PFS) and overall survival (OS) with 95% confidence intervals (CIs).

    Results
    

    PFS was significantly longer in the anlotinib group [median PFS 3.58 versus 2.56 months;hazard ratio (HR)=0.42,95% CI:0.24-0.75,P=0.003] than that in the chemotherapy group.Although anlotinib did not improve OS (median OS 5.32 versus 6.57 months;HR=1.21,95% CI:0.60-2.46,P=0.592),non-smokers derived more survival benefit from anlotinib than ever/current smokers (P_interaction for OS=0.04).In addition,similar result was found for PFS (P_interaction for PFS=0.08).Considerable improvement in disease control rate was observed in the anlotinib group over the chemotherapy group.Four (14.3%) patients in the anlotinib group versus five (18.5%) patients in the chemotherapy group had treatment-related grade 3-4 adverse events.

    Conclusion
    

    Anlotinib treatment resulted in an improvement of PFS versus chemotherapy in previously treated SCLC,with a favourable safety profile.Non-smoking seemed to be a predictive factor of anlotinib efficacy.Prospective studies were needed to confirm our findings.

    Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.